Trader Note — 2287 total
FRPT enters the post-earnings period with shorts sitting near cycle highs and the stock having shed 8% on the week — a setup that rewards watching how short positions respond to what the company just said. Short…
LBRD.K enters its Q1 2026 earnings call on May 7 having lost more than a quarter of its value in a month — and the session after last week's results print only deepened the wound. The starkest feature of this week's…
Workiva heads into its May 28 earnings with a compressed valuation, a short position near multi-month highs, and a wall of analyst target cuts fresh off the tape. The Street reaction to Tuesday's Q1 results has been…
Kimball Electronics heads into the post-earnings week with a stock that largely shrugged off a revenue miss — a quiet signal that investor patience with the electronics manufacturer's recovery thesis remains…
Rhythm Pharmaceuticals enters the back half of the week trading 10% higher, powered by a strong Q1 earnings beat that sent analysts scrambling to revise their models upward — while shorts hold their ground at the…
Limbach Holdings enters the back half of its earnings week on fire, with a Q1 2026 beat that sent the stock up 11.6% in a single session and 21.4% over the past week to $114.11 — all while its CFO has been a consistent…
SKYX Platforms Corp. heads into its Q1 2026 earnings — due May 13 — with short sellers rebuilding positions at a pace not seen in months, even as the stock bounced 8% in a single session this week. Short interest has…
Ocular Therapeutix reported Q1 results on May 5 that landed below expectations on every line — EPS of -$0.40 missed the -$0.33 estimate, and revenue of $10.8 million trailed the $12.6 million consensus. The stock…
Solana Company heads into its May 19 earnings report with short sellers actively rebuilding positions and a high-profile partnership announcement pulling in the opposite direction. The positioning story has two…
Rayonier Advanced Materials just posted Q1 results that beat revenue estimates — and still fell 6% on the week. That tension sits at the heart of this note. Revenue came in at $319 million, clearing the $302.5 million…
Arista Networks enters the post-earnings stretch with a sharp lift from analysts and an equally sharp sell from its CEO — a split signal that frames the week neatly. The most active story is on the Street. Five…
Moelis & Company heads into this week with a curious split: the stock fell nearly 9% on the week to $63.49, while short sellers were actually trimming rather than pressing. That divergence — selling pressure without a…
TSLX heads into the week after its Q1 2026 report with the borrow market fully tapped out, an elevated short score near 79, and a stock that rallied 3% on the week despite slipping into earnings — a tight, contested…
Ultragenyx Pharmaceutical heads into the post-earnings week with short sellers adding positions and analysts pulling in opposite directions — a split that reflects the market's unresolved read on whether the Q1 revenue…
PRGO reported Q1 2026 results today at the most consequential moment in its multi-year restructuring, landing an earnings beat that markets have greeted cautiously — and for good reason. Adjusted EPS came in at $0.43,…
AMC Entertainment just delivered a Q1 revenue beat — domestic box office jumped 22% — yet the lending market for its stock has simultaneously reached maximum tightness, creating an unusually charged backdrop as short…
ABEV3 erupted higher on May 5, gaining 15.3% in a single session after reporting Q1 2026 results — its biggest one-day move in recent memory — and the question now is whether the rally has left positioning and…
Veracyte enters the post-earnings stretch with short sellers sitting on a meaningful but stabilising position — a setup where the headline numbers are less interesting than the direction of travel. Short interest has…
CRTO reported Q1 2026 results this morning, delivering an earnings beat that failed to lift the stock above its recent range — and the tension between a clean headline print and a guarded revenue outlook defines the…
Fate Therapeutics enters its May 14 earnings call riding an extraordinary week — the stock doubled on a regulatory catalyst while short sellers quietly trimmed positions and call buyers dominated the options…
